Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral t-cell lymphomas: Results of a phase i study Academic Article uri icon

Overview

MeSH Major

  • Antigens, CD30
  • Antineoplastic Combined Chemotherapy Protocols
  • Immunoconjugates
  • Lymphoma, T-Cell, Peripheral

abstract

  • Brentuximab vedotin, administered sequentially with CHOP or in combination with CHP, had a manageable safety profile and exhibited substantial antitumor activity in newly diagnosed patients with CD30(+) PTCL. A randomized phase III trial is under way, comparing BV+CHP with CHOP (clinical trial No. NCT01777152).

publication date

  • October 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4171358

Digital Object Identifier (DOI)

  • 10.1200/JCO.2013.54.2456

PubMed ID

  • 25135998

Additional Document Info

start page

  • 3137

end page

  • 43

volume

  • 32

number

  • 28